点眼薬の市場規模、シェア、動向分析レポート：タイプ別、薬剤タイプ別、治療タイプ別、地域別、セグメント別予測、2025年～2030年

点眼薬市場の成長と動向

点眼薬の世界市場規模は、2030年には200億2,000万米ドルに達すると予測され、2025～2030年にかけてCAGR 6.1％で成長すると予測されています。

緑内障、加齢黄斑変性、眼症候群などの眼疾患の有病率が世界的に上昇し、点眼薬による効率的な治療に対する需要が急増しています。さらに、ドラッグデリバリー技術の進歩や防腐剤フリーの点眼薬の導入により、治療レジメンに対する患者のアドヒアランスが著しく向上しています。例えば、防腐剤無添加の点眼薬は安全性が高く、ドライアイの患者に好まれているため、より頻繁に使用できると考えられています。

白内障、緑内障、ドライアイ症候群、アレルギーなどの眼疾患の増加は、点眼薬の需要を著しく高めています。例えば、National Glaucoma Researchの報告によると、300万人以上のアメリカ人が緑内障を患っており、そのうち270万人は40歳以上の高齢者の間で流行している開放隅角緑内障です。このような有病率の急増は、世界の人口の高齢化と一致しており、これらの疾患の発生を増加させる一因となっています。その結果、目薬のような効果的な治療が急務となっています。

最適な目の健康維持と定期的な眼科検診に対する意識の高まりが、点眼薬の需要を向上させています。このような積極的なアプローチは、眼科の問題をより早く治療するのに役立ち、眼科医療提供者や目薬製造企業が支援することを可能にしています。例えば、AlconやBausch+Lombのような企業は、さまざまな目の問題のために特別な目薬を作り、それによって市場の成長を促進しています。

点眼薬市場レポートハイライト

• 市場成長段階は中程度であり、そのペースは、技術、製剤、点眼薬送達システムの進歩など、いくつかの要因によって加速しています。
• 2024年には、保存型マルチ用量点眼薬セグメントが48.5％の最大収益シェアを占めました。
• 処方薬セグメントは、2024年に61.3%の最大の収益シェアを占め、2025～2030年にかけて最も速いCAGRを達成する見込みです。
• ドライアイセグメントは、2024年に最大の市場シェアを占めました。これは、長時間のデジタル機器の使用、環境要因、高齢化により、スポイトによる特定の治療の必要性が高まっているためです。
• 北米の点眼薬市場は2024年に44.75％で世界市場を独占.

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 点眼薬市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 点眼薬市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 点眼薬市場：タイプ別、推定・動向分析

• 定義と範囲
  • ユニドーズ点眼薬
  • 保存用多回分点眼薬
  • 防腐剤不使用の多回分点眼薬
• タイプ別市場シェア、2024年と2030年
• セグメントダッシュボード
• タイプ別点眼薬の世界市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 単回分点眼薬
  • 保存された多回分点眼薬
  • 防腐剤不使用の多回分点眼薬

第5章 点眼薬市場：薬剤タイプ別、推定・動向分析

• 定義と範囲
  • 処方薬
  • 市販薬
• 薬剤タイプ別市場シェア、2024年と2030年
• セグメントダッシュボード
• 薬剤タイプ別点眼薬の世界市場展望
• 2018～2030年の市場規模と予測と動向分析
  • 処方薬
  • 市販薬

第6章 点眼薬市場：治療タイプ別、推定・動向分析

• 定義と範囲
  • ドライアイ
  • 緑内障
  • アレルギー
  • 結膜炎
  • その他
• 治療タイプ別市場シェア、2024年と2030年
• セグメントダッシュボード
• 治療タイプ別点眼薬の世界市場展望
• 2018～2030年の市場規模と予測と動向分析
  • ドライアイ
  • 緑内障
  • アレルギー
  • 結膜炎
  • その他

第7章 点眼薬市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
  • イノベーター
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • AptarGroup, Inc
  • Silgan Dispensing Systems
  • Alcon plc
  • Pfizer
  • Bausch & Lomb Incorporated
  • Novartis AG
  • AbbVie Inc
  • Santen Pharmaceutical Co., Ltd.
  • Johnson & Johnson Vision
  • Similasan Corporation

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 4 Global ophthalmic eye dropper market, by drug type, (USD million) 2018 - 2030
• Table 5 Global ophthalmic eye dropper market, by treatment type, (USD million) 2018 - 2030
• Table 6 North America ophthalmic eye dropper market, by country, 2018 - 2030 (USD Million)
• Table 7 North America ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 8 North America ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 9 North America ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 10 U.S. ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 11 U.S. ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 12 U.S. ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 13 Canada ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 14 Canada ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 15 Canada ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 16 Mexico ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 17 Mexico ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 18 Mexico ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 19 Europe ophthalmic eye dropper market, by country, 2018 - 2030 (USD Million)
• Table 20 Europe ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 21 Europe ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 22 Europe ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 23 UK ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 24 UK ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 25 UK ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 26 Germany ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 27 Germany ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 28 Germany ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 29 France ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 30 France ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 31 France ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 32 Italy ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 33 Italy ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 34 Italy ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 35 Spain ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 36 Spain ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 37 Spain ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 38 Norway ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 39 Norway ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 40 Norway ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 41 Sweden ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 42 Sweden ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 43 Sweden ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 44 Denmark ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 45 Denmark ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 46 Denmark ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific ophthalmic eye dropper market, by country, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 51 Japan ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 52 Japan ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 53 Japan ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 54 China ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 55 China ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 56 China ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 57 India ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 58 India ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 59 India ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 60 Australia ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 61 Australia ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 62 Australia ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 63 South Korea ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 64 South Korea ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 65 South Korea ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 66 Thailand ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 67 Thailand ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 68 Thailand ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 69 Latin America ophthalmic eye dropper market, by country, 2018 - 2030 (USD Million)
• Table 70 Latin America ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 71 Latin America ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 72 Latin America ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 73 Brazil ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 74 Brazil ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 75 Brazil ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 76 Argentina ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 77 Argentina ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 78 Argentina ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa ophthalmic eye dropper market, by country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 83 South Africa ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 84 South Africa ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 85 South Africa ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 89 UAE ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 90 UAE ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 91 UAE ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)
• Table 92 Kuwait ophthalmic eye dropper market, by type, 2018 - 2030 (USD Million)
• Table 93 Kuwait ophthalmic eye dropper market, by drug type, 2018 - 2030 (USD Million)
• Table 94 Kuwait ophthalmic eye dropper market, by treatment type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Ophthalmic eye dropper market segmentation
• Fig. 7 Market driver analysis (Current & future impact)
• Fig. 8 Market restraint analysis (Current & future impact)
• Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 10 Porter's Five Forces Analysis
• Fig. 11 Ophthalmic eye dropper market, type outlook key takeaways (USD Million)
• Fig. 12 Ophthalmic eye dropper market: type movement analysis, 2023 & 2030 (USD Million)
• Fig. 13 Unidose eye droppers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 14 Preserved multi-dose eye droppers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 15 Preservative-free multi-dose eye droppers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 16 Ophthalmic eye dropper market, drug type outlook key takeaways (USD Million)
• Fig. 17 Ophthalmic eye dropper market: Drug type movement analysis, 2023 & 2030 (USD Million)
• Fig. 18 Prescription drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 OTC drugs market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Ophthalmic eye dropper market, treatment type outlook key takeaways (USD Million)
• Fig. 21 Ophthalmic eye dropper market: Treatment type movement analysis, 2023 & 2030 (USD Million)
• Fig. 22 Dry eye market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Glaucoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Allergies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Conjunctivitis market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Ophthalmic eye dropper market: Regional key takeaways (USD Million)
• Fig. 28 Ophthalmic eye dropper market: Regional outlook, 2023 & 2030, USD Million
• Fig. 29 North America ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 US ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Canada ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Mexico ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Europe ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 UK ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Germany ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 France ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Spain ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Italy ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Sweden ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Norway ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Denmark ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Asia Pacific ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 China ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Japan ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 India ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 South Korea ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Australia ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Thailand ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Latin America ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Brazil ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Argentina ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Middle East and Africa ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 South Africa ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Saudi Arabia ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 UAE ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Kuwait ophthalmic eye dropper market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 List of key emerging company's/technology disruptors/innovators

Ophthalmic Eye Dropper Market Growth & Trends:

The global ophthalmic eye dropper market size is anticipated to reach USD 20.02 billion in 2030 and is anticipated to grow at a CAGR of 6.1% from 2025 to 2030. The rising prevalence of eye disorders such as glaucoma, age-related macular degeneration, and eye syndrome among the aging population worldwide has surged the demand for efficient treatments delivered through eye droppers. Moreover, advancements in drug delivery technologies and the introduction of preservative-free eye drops have notably improved patient adherence to treatment regimens. For instance, preservative-free drops are considered safer and preferred by individuals with dry eyes, thus allowing more frequent use.

The rise in eye conditions such as cataracts, glaucoma, dry eye syndrome, and allergies has significantly bolstered the demand for ophthalmic eye drops. For instance, as reported by the National Glaucoma Research, over 3 million Americans live with glaucoma, out of which 2.7 million are affected by the prevalent open-angle glaucoma among those aged 40 and older. This surge in prevalence aligns with the aging global population, contributing to the increasing occurrence of these conditions. Consequently, there's a pressing necessity for effective treatments like eye drops to address these escalating eye health challenges.

The increased awareness about maintaining optimal eye health and regular eye check-ups has improved the demand for ophthalmic eye drops. This proactive approach helps treat ophthalmic issues quicker which allows eye care providers and eye drops manufacturing companies to assist. For instance, companies like Alcon and Bausch + Lomb have made special eye drops for different eye problems, thereby fueling the market growth.

Ophthalmic Eye Dropper Market Report Highlights:

• The market growth stage is medium, and the pace is identified as accelerating owing to several factors, such as advancements in technology, formulations, and delivery systems for ophthalmic eye drops, which have significantly contributed to this growth.
• The preserved multi-dose eye droppers segment accounted for the largest revenue share of 48.5% in 2024.
• The prescription drugs segment accounted for the largest revenue share of 61.3% in 2024 and is expected to attain the fastest CAGR from 2025 to 2030.
• The dry eye segment accounted for the largest market share in 2024, due to prolonged digital device use, environmental factors, and an aging population, which has heightened the need for specific treatments administered via eye droppers.
• North America ophthalmic eye dropper market dominated the global market 44.75% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Type
  • 1.1.2. Drug Type
  • 1.1.3. Treatment
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for Primary Interviews in North America
    • 1.3.5.2. Data for Primary Interviews in Europe
    • 1.3.5.3. Data for Primary Interviews in Asia Pacific
    • 1.3.5.4. Data for Primary Interviews in Latin America
    • 1.3.5.5. Data for Primary Interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Drug Type
  • 2.2.3. Treatment Type
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ophthalmic Eye Dropper Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of eye disorders
    • 3.2.1.2. Technological advancements in drug delivery systems
    • 3.2.1.3. Aging population and lifestyle changes
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited patient compliance
• 3.3. Ophthalmic Eye Dropper Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Ophthalmic Eye Dropper Market: Type Estimates & Trend Analysis

• 4.1. Definitions and Scope
  • 4.1.1. Unidose eye droppers
  • 4.1.2. Preserved multi-dose eye droppers
  • 4.1.3. Preservative-free multi-dose eye droppers
• 4.2. Type Market Share, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Global Ophthalmic Eye Dropper Market by Type Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. Unidose eye droppers
    • 4.5.1.1. Unidose eye Droppers Market Estimates and Forecast 2018 to 2030 (USD Million)
  • 4.5.2. Preserved multi-dose eye droppers
    • 4.5.2.1. Preserved multi-dose eye droppers market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Preservative-free multi-dose eye droppers
    • 4.5.3.1. Preservative-free multi-dose eye Droppers Market Estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Ophthalmic Eye Dropper Market: Drug Type Estimates & Trend Analysis

• 5.1. Definitions and Scope
  • 5.1.1. Prescription drugs
  • 5.1.2. OTC drugs
• 5.2. Drug Type Market Share, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Global Ophthalmic Eye Dropper Market by Drug Type Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5.1. Prescription drugs
    • 5.5.1.1. Prescription drugs market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.2. OTC drugs
    • 5.5.2.1. OTC drugs market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Ophthalmic Eye Dropper Market: Treatment Type Estimates & Trend Analysis

• 6.1. Definitions and Scope
  • 6.1.1. Dry Eye
  • 6.1.2. Glaucoma
  • 6.1.3. Allergies
  • 6.1.4. Conjunctivitis
  • 6.1.5. Others
• 6.2. Treatment Type Market Share, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. Global Ophthalmic Eye Dropper Market by Treatment Type Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5.1. Dry Eye
    • 6.5.1.1. Dry eye market estimates and forecasts for 2018 to 2030 (USD Million)
  • 6.5.2. Glaucoma
    • 6.5.2.1. Glaucoma market estimates and forecasts for 2018 to 2030 (USD Million)
  • 6.5.3. Allergies
    • 6.5.3.1. Allergies market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.4. Conjunctivitis
    • 6.5.4.1. Conjunctivitis market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.5. Others
    • 6.5.5.1. Others market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Ophthalmic Eye Dropper Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement scenario
    • 7.5.1.5. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement scenario
    • 7.6.1.5. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Reimbursement scenario
    • 7.6.5.5. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Reimbursement scenario
    • 7.6.6.5. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Reimbursement scenario
    • 7.6.7.5. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Competitive scenario
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Reimbursement scenario
    • 7.6.8.5. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement scenario
    • 7.9.3.5. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Competitive scenario
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Reimbursement scenario
    • 7.9.4.5. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. AptarGroup, Inc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Silgan Dispensing Systems
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Alcon plc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Pfizer
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Bausch & Lomb Incorporated
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Novartis AG
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. AbbVie Inc
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Santen Pharmaceutical Co., Ltd.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Johnson & Johnson Vision
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Similasan Corporation
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives